Neue Therapieoption für die Myelofibrose: JAK 1/2 inhibitors lead to clinically significant remissions

N. Von Bubnoff

doi:10.1007/s00761-012-2283-1

Neue Therapieoption für die Myelofibrose: JAK 1/2 inhibitors lead to clinically significant remissions

Translated title of the contribution: New therapeutic option for myelofibrosis: JAK 1/2 inhibitors lead to clinically significant remissions

N. Von Bubnoff^*

^*Corresponding author for this work

Clinic of Hematology and Oncology

Translated title of the contribution	New therapeutic option for myelofibrosis: JAK 1/2 inhibitors lead to clinically significant remissions
Original language	German
Journal	Onkologe
Volume	18
Issue number	7
Pages (from-to)	624-626
Number of pages	3
ISSN	0947-8965
DOIs	https://doi.org/10.1007/s00761-012-2283-1
Publication status	Published - 07.2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00761-012-2283-1

Cite this

@article{baab72f450414eacb384a7f577982023,

title = "Neue Therapieoption f{\"u}r die Myelofibrose: JAK 1/2 inhibitors lead to clinically significant remissions",

author = "\{Von Bubnoff\}, N.",

year = "2012",

month = jul,

doi = "10.1007/s00761-012-2283-1",

language = "Deutsch",

volume = "18",

pages = "624--626",

journal = "Onkologe",

issn = "0947-8965",

publisher = "Springer Medizin",

number = "7",

}

TY - JOUR

T1 - Neue Therapieoption für die Myelofibrose: JAK 1/2 inhibitors lead to clinically significant remissions

AU - Von Bubnoff, N.

PY - 2012/7

Y1 - 2012/7

UR - https://www.scopus.com/pages/publications/84865261034

U2 - 10.1007/s00761-012-2283-1

DO - 10.1007/s00761-012-2283-1

M3 - Zeitschriftenaufsätze

AN - SCOPUS:84865261034

SN - 0947-8965

VL - 18

SP - 624

EP - 626

JO - Onkologe

JF - Onkologe

IS - 7

ER -

Neue Therapieoption für die Myelofibrose: JAK 1/2 inhibitors lead to clinically significant remissions

UN SDGs

Access to Document

Other files and links

Cite this